 Aileron Therapeutics Inc NASDAQ: ALRN presented new clinical data at the European Society of Medical Oncology ESMO21 Virtual Congress 2021 for ALRN-6924, a chemoprotective agent. Aileron is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapys attack on cancer cells. 